Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD 360324

Drug Profile

PD 360324

Alternative Names: PD-0360324; PD-360,324

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Cutaneous lupus erythematosus; Pulmonary sarcoidosis; Rheumatoid arthritis

Most Recent Events

  • 30 Nov 2022 Phase-II development in Solid tumours is ongoing in USA, Australia, Canada, France, Japan, Poland, Taiwan, and United Kingdom (NCT02554812)
  • 28 Sep 2021 Pfizer plans a phase III trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO) (NCT05059522)
  • 09 Jan 2020 PD 360324 is still in phase II trials for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA, United Kingdom, Australia, Canada, France, Germany, Netherlands, Japan (IV) (NCT02554812) (EudraCT2015-002552-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top